FY2027 Earnings Forecast for Zevra Therapeutics, Inc. Issued By Roth Capital (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA) – Research analysts at Roth Capital increased their FY2027 earnings per share (EPS) estimates for Zevra Therapeutics in a research report issued on Wednesday, May 8th. Roth Capital analyst J. Aschoff now expects that the company will post earnings per share of $1.98 for the year, up from their prior forecast of $1.89. The consensus estimate for Zevra Therapeutics’ current full-year earnings is ($1.65) per share.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.20). The company had revenue of $13.22 million for the quarter, compared to the consensus estimate of $13.35 million. Zevra Therapeutics had a negative net margin of 167.69% and a negative return on equity of 68.41%.

Other equities analysts have also issued research reports about the company. Maxim Group lifted their target price on Zevra Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zevra Therapeutics in a research report on Monday, April 1st. William Blair reissued an “outperform” rating on shares of Zevra Therapeutics in a research report on Tuesday, March 12th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 price target on shares of Zevra Therapeutics in a report on Wednesday, April 3rd. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $19.50.

Zevra Therapeutics Stock Performance

Shares of NASDAQ:ZVRA opened at $5.03 on Thursday. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 0.08. The company has a market capitalization of $218.45 million, a price-to-earnings ratio of -3.90 and a beta of 1.87. The firm has a 50 day moving average of $5.33 and a 200 day moving average of $5.38. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $7.28.

Institutional Trading of Zevra Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new stake in shares of Zevra Therapeutics during the third quarter worth $71,000. Commonwealth Equity Services LLC acquired a new stake in Zevra Therapeutics during the 3rd quarter worth about $52,000. Raymond James Financial Services Advisors Inc. acquired a new position in shares of Zevra Therapeutics in the third quarter valued at about $126,000. Stratos Wealth Partners LTD. purchased a new position in shares of Zevra Therapeutics in the third quarter worth about $338,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Zevra Therapeutics during the third quarter worth about $977,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.